SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(B) OR (G) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Dova Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

 

81-3858961

(State of Incorporation or Organization)

 

(I.R.S. Employer Identification No.)

 

 

 

240 Leigh Farm Road, Suite 245
Durham, North Carolina

 

27707

(Address of principal executive offices)

 

(Zip code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered

 

Name of exchange on which
each class is to be registered

Common Stock, $0.001 par value per share

 

The NASDAQ Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.      x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.      o

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.                ¨

 

Securities Act registration statement number to which the form relates:  333-218479

 

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 

 



 

Item 1.                   Description of Registrant’s Securities to be Registered.

 

Dova Pharmaceuticals, Inc. (the “Registrant”) hereby incorporates by reference the description of its common stock, par value $0.001 per share, to be registered hereunder contained under the heading “Description of Capital Stock” in the Registrant’s Registration Statement on Form S-1 (File No. 333-218479), as originally filed with the Securities and Exchange Commission (the “Commission”) on June 2, 2017, as subsequently amended on June 9, 2017, and June 19, 2017 (the “Registration Statement”), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, which description included in such prospectus shall be deemed to be incorporated by reference herein.

 

Item 2.                   Exhibits.

 

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

2



 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dova Pharmaceuticals, Inc.

 

 

 

 

Date: June 26, 2017

By:

/s/ Alex Sapir

 

 

Name: Alex Sapir

 

 

Title: President and Chief Executive Officer

 

3